FreeCME

Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer

CME: 1.0

Target Audience

This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview

Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to improve care and outcomes for these patient populations. In this activity, expert faculty will discuss the latest advances in testing and treatment of advanced non-small cell lung cancer (NSCLC) and current guideline recommendations surrounding immunotherapy. Strategies for reducing disparities in care access and treatment for NSCLC in rural and underserved settings will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on September 24, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply biomarker testing results to guide treatment decisions for NSCLC
  • Differentiate treatment options for advanced NSCLC based on clinical safety and efficacy data
  • Integrate clinical evidence and current guideline recommendations on immunotherapies into treatment plans for patients with advanced NSCLC
  • Implement interprofessional strategies for reducing disparities in care access and treatment for NSCLC in rural and underserved settings

Post a comment to this article